Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in ...

PDS Biotechnology (PDSB) announced the publication of circulating tumor DNA results for its lead immunotherapy candidate, Versamune HPV, in ...

The trial will evaluate the efficacy of Versamune® HPV in combination with pembrolizumab for the treatment of HPV16-positive recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV ...

PDS Biotechnology Corporation (NASDAQ:PDSB) stock has reached a 52-week low, trading at $1.3, as investors navigate a tumultuous market environment. According to InvestingPro analysis, the stock ...

PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination ...

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune ...